EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Heparanase gene deficiency suppresses atherosclerosis progression and enhances plaque stability in apolipoprotein E gene knockout mice with diabetes

Tien K Nguyen, Amy A Baxter, Chloe Bourchier, Thanh Kha Phan, Enoch Chan, Ivan K H Poon, Shane R Thomas, Mark D Hulett iD

Clinical Science · 12.08.2026 · 140 (8) · 1599-1615

DOI: 10.1042/cs20250817 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Science, online erschienen am 10.07.2026. Verfasst von Tien K Nguyen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria 3086, Australia. Hauptthemen laut MEDLINE: Glucuronidase, Plaque, Atherosclerotic, Diabetes Mellitus, Experimental, Atherosclerosis. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Future Fund Cardiovascular Health Mission Grant, Wellcome Trust, Australian National Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes mellitus accelerates the development of atherosclerotic cardiovascular disease. Heparanase, the sole enzyme responsible for cleaving heparan sulfates in the endothelial glycocalyx and subendothelial extracellular matrix, plays important pro-inflammatory roles in diabetes and atherosclerosis. However, the role of heparanase in diabetes-accelerated atherosclerosis is unknown. This study investigated the impact of heparanase gene-deficiency on atherosclerosis development in non-diabetic and streptozotocin (STZ)-treated, diabetic apolipoprotein E gene knockout (ApoE−/−) mice fed a normal chow diet for eight weeks. At the study endpoint, atherosclerotic lesion size and stability phenotype, along with blood glucose, serum lipid, and pro-inflammatory cytokine profiles were assessed. Compared to non-diabetic control ApoE−/− mice, STZ-treated, diabetic ApoE−/− mice exhibited significant increases in blood glucose, serum lipids, circulating MCP-1 and IL-6 levels, and the development of atherosclerotic lesion burden in the aortic sinus and aorta. While heparanase deficiency did not affect blood glucose or serum lipid levels, it significantly reduced the diabetes-dependent increase in circulating MCP-1 levels and diabetes-accelerated development of atherosclerotic lesions in the aortic sinus and aorta. Analysis of lesion composition and phenotype showed that diabetic ApoE−/− mice commonly exhibited advanced atherosclerotic lesions with well-developed necrotic cores, whereas diabetic heparanase-deficient ApoE−/− mice displayed early-stage atherosclerotic lesions, characterised by significantly smaller necrotic cores and increased collagen and smooth muscle cell content. The present study demonstrates that heparanase is a prominent pro-inflammatory protein driving the diabetes-accelerated formation of advanced atherosclerotic lesions with an unstable phenotype. Heparanase therefore represents a new therapeutic target for suppressing atherosclerotic cardiovascular disease in people with diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucuronidasePlaque, AtheroscleroticDiabetes Mellitus, ExperimentalAtherosclerosisApolipoproteins EAnimalsHeparanaseDisease ProgressionMaleBlood GlucoseMice, Knockout, ApoEMice, Inbred C57BLMice, KnockoutLipidsAortaChemokine CCL2Mice

Stichwörter der Autor:innen

atherosclerosisdiabetesheparanaseinflammation

Substanzen

GlucuronidaseHeparanaseBlood GlucoseApolipoproteins ELipidsChemokine CCL2

Autor:innen und Institutionen

  • Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria 3086, Australia.
  • Department of Pathology, School of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, New South Wales 2052, Australia.

ORCID-Profile: Mark D Hulett

Förderung

  • Medical Research Future Fund Cardiovascular Health Mission Grant
  • Wellcome Trust
  • Australian National Heart Foundation

Zitieren

APA

Nguyen, T. K., Baxter, A. A., Bourchier, C., Phan, T. K., Chan, E., Poon, I. K. H., Thomas, S. R., & Hulett, M. D. (2026). Heparanase gene deficiency suppresses atherosclerosis progression and enhances plaque stability in apolipoprotein E gene knockout mice with diabetes. Clinical Science, 140(8), 1599-1615. https://doi.org/10.1042/cs20250817

Vancouver

Nguyen TK, Baxter AA, Bourchier C, Phan TK, Chan E, Poon IKH, et al. Heparanase gene deficiency suppresses atherosclerosis progression and enhances plaque stability in apolipoprotein E gene knockout mice with diabetes. Clinical Science. 2026;140(8):1599-1615. doi:10.1042/cs20250817

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Tien K and Baxter, Amy A and Bourchier, Chloe and Phan, Thanh Kha and Chan, Enoch and Poon, Ivan K H and Thomas, Shane R and Hulett, Mark D},
  title = {Heparanase gene deficiency suppresses atherosclerosis progression and enhances plaque stability in apolipoprotein E gene knockout mice with diabetes},
  journal = {Clinical Science},
  year = {2026},
  volume = {140},
  number = {8},
  pages = {1599--1615},
  doi = {10.1042/cs20250817}
}
Kostenlos starten →